Cantor Fitzgerald Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $220.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Cantor Fitzgerald from $150.00 to $220.00 in a report released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a buy rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. UBS Group raised their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a buy rating in a research note on Friday, June 28th. Evercore ISI upped their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an outperform rating in a research note on Tuesday, June 25th. Royal Bank of Canada increased their price target on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an outperform rating in a report on Tuesday, June 25th. Finally, Citigroup boosted their price objective on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a buy rating in a report on Tuesday, June 25th. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $256.73.

Alnylam Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:ALNY opened at $236.48 on Monday. The company has a market cap of $29.91 billion, a price-to-earnings ratio of -88.24 and a beta of 0.37. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $263.73. The company has a 50-day moving average price of $195.54 and a 200 day moving average price of $172.04.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter last year, the firm posted ($1.40) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -3.99 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,450 shares of company stock valued at $15,287,984. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. ANTIPODES PARTNERS Ltd boosted its holdings in Alnylam Pharmaceuticals by 69.1% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after acquiring an additional 77,307 shares in the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after buying an additional 4,809 shares during the last quarter. Finally, Westpac Banking Corp lifted its stake in shares of Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 566 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.